Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioSante Pharmaceuticals Names Joy A. Thomas

Abstract:
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced the appointment of Joy A. Thomas as vice president of corporate development. Ms. Thomas will be integral to BioSante implementing its corporate development strategies, including collaborations and licensing.

BioSante Pharmaceuticals Names Joy A. Thomas

LINCOLNSHIRE, IL | Posted on September 5th, 2007

Ms. Thomas comes to BioSante after 13 years with Baxter Healthcare Corporation where she was most recently Senior Director, Global Strategy & Business Development for its Renal Division. Earlier she was Director, Strategic Marketing and Planning for its Medication Delivery Division. Ms. Thomas holds a Bachelor of Science degree in Finance and Russian from the University of Illinois, and a Master of Business Administration in International Business and Finance from the University of Chicago.

"We are very pleased to have Joy Thomas joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer. "Joy's experience and expertise will be invaluable in assessing BioSante's strategic alternatives in view of the excellent progress we have made, especially related to FDA clarity on the development of LibiGel® in the treatment of female sexual dysfunction. We remain dedicated to our objective of maximizing stockholder value and believe Joy will be integral to this endeavor."

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.

For more information, please click here

Contacts:
BioSante Pharmaceuticals, Inc.
Phillip Donenberg
(847) 478-0500

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

Nanotubes that build themselves April 14th, 2017

Announcements

Geoffrey Beach: Drawn to explore magnetism: Materials researcher is working on the magnetic memory of the future April 25th, 2017

Using light to propel water : With new method, MIT engineers can control and separate fluids on a surface using only visible light April 25th, 2017

Graphene holds up under high pressure: Used in filtration membranes, ultrathin material could help make desalination more productive April 24th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project